Sign in Subscribe
Cancer research

Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A New Approach

Strategic Insights

— 1 min read

A study published in the Journal of the American Medical Association (JAMA) Oncology has introduced a new approach to treating advanced hepatocellular carcinoma (HCC). The research, conducted by investigators at the University of Palermo, aimed to compare the health-related quality of life (HR-QoL) effects associated with different first-line treatments for unresectable or advanced HCC. The study found that atezolizumab plus bevacizumab provides the best balance between quality of life preservation and overall survival benefit compared to other systemic therapy options.

Key Takeaways:

  • Researchers at the University of Palermo conducted a network meta-analysis to compare HR-QoL effects across different first-line treatments for unresectable or advanced HCC.
  • The study included 7 HR-QoL items from 9 randomized clinical trials enrolling 6425 patients.
  • SUCRA calculations showed that atezolizumab plus bevacizumab had the highest probability of reducing deterioration of global health status and QoL (85%), abdominal swelling (95%), jaundice (89%), and pain (86%).
  • Integrate Health-related Quality of Life (HR-QoL) and overall survival to offer a more patient-centered approach for treatment selection in clinical practice.
  • Atezolizumab plus bevacizumab outperformed all other treatments across all HR-QoL items when integrating HR-QoL with overall survival.
  • This integrated approach to treatment selection may improve patient outcomes and quality of life.

Statistics:

  • 6425 patients were enrolled in the 9 randomized clinical trials included in the study.
  • 7 HR-QoL items were analyzed in the study, including global health status, QoL, abdominal swelling, pain, jaundice, and other symptoms.
  • SUCRA calculations showed that atezolizumab plus bevacizumab had a 85% probability of reducing deterioration of global health status and QoL.
  • Atezolizumab plus bevacizumab had a 95% probability of reducing abdominal swelling and a 89% probability of reducing jaundice.
  • The study found that atezolizumab plus bevacizumab outperformed all other treatments across all HR-QoL items when integrating HR-QoL with overall survival.

Sources:

  • NewsRx. Studies from University of Palermo Provide New Data on Liver Cancer (Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis). Immunotherapy Weekly. August 27, 2025; p 3334.
  • JAMA Oncology. Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. 2025.

Read more